human allogeneic iPS cell derived-cardiomyocyte sheet transplantation (Cuorips/Osaka)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namehuman allogeneic iPS cell derived-cardiomyocyte sheet transplantation (Cuorips/Osaka)
Drug Alias NameiPS-derived cardiomyocyte sheet (Cuorips/Otsuka)cardiomyocyte therapy (Cuorips/Osaka)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Cardiac myocyte stem cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsMyocardial IschemiaHeart FailureCardiomyopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOsaka University
China Registration ClassN/A

Develop Information

Active CompaniesCuorips Inc
Inactive CompaniesN/A
Active IndicationsMyocardial IschemiaHeart FailureCardiomyopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A